Log in

NASDAQ:HTGMHTG Molecular Diagnostics Stock Price, Forecast & News

$0.65
-0.03 (-4.44 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.60
Now: $0.65
$0.68
50-Day Range
$0.42
MA: $0.62
$0.83
52-Week Range
$0.27
Now: $0.65
$1.64
Volume8.69 million shs
Average Volume6.58 million shs
Market Capitalization$43.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Read More
HTG Molecular Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.20 million
Book Value$0.41 per share

Profitability

Net Income$-19,300,000.00
Net Margins-106.35%

Miscellaneous

Employees107
Market Cap$43.33 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

How has HTG Molecular Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HTGM stock has increased by 63.8% and is now trading at $0.6458. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of HTG Molecular Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HTG Molecular Diagnostics.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its earnings results on Wednesday, May, 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $2.23 million for the quarter, compared to analysts' expectations of $2.28 million. HTG Molecular Diagnostics had a negative return on equity of 90.50% and a negative net margin of 106.35%. View HTG Molecular Diagnostics' earnings history.

What price target have analysts set for HTGM?

4 equities research analysts have issued 12 month target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $0.70 to $1.50. On average, they anticipate HTG Molecular Diagnostics' share price to reach $1.18 in the next twelve months. This suggests a possible upside of 81.9% from the stock's current price. View analysts' price targets for HTG Molecular Diagnostics.

What are Wall Street analysts saying about HTG Molecular Diagnostics stock?

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
  • 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (5/22/2020)
  • 2. Canaccord Genuity analysts commented, "We were pleased to host newer HTG CEO John Lubniewski and CFO Conference last week in Boston. Our key takeaways: (1) HTG is making a bigger push to develop and launch novel diagnostic test launches in breast and lung cancer; (2) HTG is not getting any credit in its stock price for strong 80%+ Y/Y growth in its base RUO profiling business; and (3) HTG has taken adverse lumps" because they haven’t converted a CDx yet (yet they have over 70 active global pharma programs). We reiterate our BUY rating and trim our PT to $3, which we would be inclined to raise should HTG hit" on one of its pharma collaborations. EdgeSeq Breast Total Lung." (8/13/2019)

Has HTG Molecular Diagnostics been receiving favorable news coverage?

Media stories about HTGM stock have trended negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future. View the latest news about HTG Molecular Diagnostics.

Who are some of HTG Molecular Diagnostics' key competitors?

What other stocks do shareholders of HTG Molecular Diagnostics own?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
  • Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)
  • Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $0.65.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $43.33 million and generates $19.20 million in revenue each year. The medical research company earns $-19,300,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.